Loading stock data…
AKBA
$1.40+0.02 (+1.45%)
Market ClosedLast close May 1
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Akebia Therapeutics, Inc. in the Healthcare sector is trading at $1.40. The stock is currently near its 52-week low of $1.14, remaining 33.3% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why AKBA maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.40
Potential Upside
5%
Whystock Fair Value$1.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$380.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-16.39%
Volume
Today's trading volume
2.52M
Recent News
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +64.71% and +29.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
New Strong Sell Stocks for April 28th
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks
The United States market has shown robust performance, climbing 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In this context of market growth, identifying stocks with strong financials can be crucial for investors seeking potential opportunities. Penny stocks, though often seen as a term from earlier market days, still represent a segment where smaller or newer companies might offer both affordability and significant growth potential.